Treatment-free Remission After Achieving Sustained MR4.5 on Nilotinib (ENESTop)
Status:
Active, not recruiting
Trial end date:
2025-02-06
Target enrollment:
Participant gender:
Summary
A clinical research study to find out if it is safe to stop the drug nilotinib (Tasigna) in
chronic myeloid leukemia (CML) patients. Patients who started treatment with imatinib
(Gleevec) when they were first diagnosed with CML, then switched to nilotinib (Tasigna) for
at least 2 years with the combined time on imatinib (Gleevec) and nilotinib (Tasigna) for at
least 3 years and have very small amount of leukemia cells remaining after the nilotinib
(Tasigna) treatment will qualify for the study.